Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer

Table 2 MLH1/MSH2 expression and other clinicopathological parameters

	MLH1 (+)	MLH1 (-)	P	MSH2 (+)	MSH2 (-)	P
PT Crohn1			0.571			0.492
-	42 (93.3)	26 (89.7)		63 (91.3)	3 (60)
+	3 (6.7)	3 (10.3)		6 (8.7)	2 (40)
PT Lymph2			0.953			0.172
-	37 (82.2)	24 (82.8)		58 (84.1)	3 (60)
+	8 (17.8)	5 (17.2)		11 (15.9)	2 (40)
Tumor border			0.747			0.184
Expansive	7 (15.6)	3 (10.3)		8 (11.6)	2 (40)
Infiltrating	17 (37.8)	13 (44.8)		29 (42)	1 (20)
Both	21 (46.7)	13 (44.8)		32 (46.4)	2 (40)
Invasion level			0.865			0.002
Submucosa	1 (2.2)	0 (0)		0 (0)	1 (20)
Muscularis	7 (15.6)	4 (13.8)		10 (14.5)	1 (20)
Subserosa	33 (73.3)	22 (75.9)		52 (75.4)	3 (60)
Serosa	4 (8.9)	3 (10.3)		7 (10.1)	0 (0)
PNI3			0.633			0.394
-	27 (60)	19 (65.5)		42 (60.9)	4 (80)
+	18 (40)	10 (34.5)		27 (39.1)	1 (20)
LVI4			0.522
-	7 (15.6)	3 (10.3)		9 (13)	4 (80	0.660
+	38 (84.4)	26 (89.7)		60 (87)	1 (20)
BVI5			0.114			0.927
-	38 (84.4)	20 (69)		54 (78.3)	4 (80)
+	7 (15.6)	9 (31)		15 (21.7)	1 (20)
LN metastasis			0.146			0.816
-	25 (58.1)	21 (75)		43 (65.2)	3 (60)
+	18 (41.9)	7 (25)		23 (34.8)	2 (20)
Survival			0.035			0.562
Disease-free	19 (45.2)	13 (50)		31 (48.4)	2 (40)
Recurrence/metastasis	2 (4.8)	6 (23.1)		7 (10.9)	1 (20)
Extend	21 (50)	7 (26.9)		26 (40.6)	2 (40)
Stage (AJCC- 2002)6			0.119			0.520
1	5 (11.6)	3 (10.7)		6 (9.1)	2 (40)
2	18 (41.8)	17 (60.7)		34 (51.5)	1 (20)
3	16 (37.2)	5 (17.8)		20 (30.3)	1 (20)
4	4 (9.4)	3 (10.7)		6 (9.1)	1 (20)
p53 expression			0.227			< 0.05
≤ 10%	27 (60)	16 (57.1)		0 (0)	5 (100)
> 10 %	18 (40)	12 (42.9)		74 (100)	0 (0)

¹Peritumoral Crohn-like inflammation;

²Peritumoral lymphocytic inflammation;

³Perineural invasion;

⁴Lymph vessel invasion;

⁵Blood vessel invasion;

⁶American Joint Committee of Cancer.